.svg){kind=small}
May-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
Emerald Bay Extracts concentrated 53.13% of May 2026 sales in Capsules with year-over-year decline of 41.43% and month-over-month decline of 8.46%, while Concentrates held 24.80% share with a 0.75% year-over-year dip and a 15.20% month-over-month drop; Tincture & Sublingual expanded to 22.06% share with 478.29% year-over-year growth but slipped 0.14% month over month. Despite a 5.21% year-over-year decrease in average price to $32.87 and a brand-level sales decline of 16.33% year over year, the brand’s Capsules rank at 6 in California indicates reliance on a high-share but contracting anchor category, implying that mix-driven exposure to Capsules is pulling overall performance down even as Tincture & Sublingual offsets some losses.
The rotation toward Tincture & Sublingual, up 478.29% year over year to 22.06% share while Capsules fell 41.43% year over year and Concentrates slid 15.20% month over month, suggests the brand is migrating demand toward formats with less downside volatility; however, the 8.46% month-over-month decline in Capsules combined with the 0.14% month-over-month slip in Tincture & Sublingual shows short-term softness across formats. With Capsules still at 53.13% share and ranked 6 in California, the implication is that near-term positioning hinges on stabilizing the lead category while intentionally building Tincture & Sublingual to rebalance mix risk and reduce sensitivity to category-specific declines.
Competitive Landscape
Emerald Bay Extracts ranks #6 in CA Capsules in May 2026, slipping 1 position year over year from #5 while also falling 1 spot versus February 2026 when it held #5; against peers, Breez moved up from #2 to #1 despite a 44.6% YoY sales decline and Kikoko moved down from #4 to #5 with a 39.8% YoY drop, indicating Emerald Bay Extracts’ relative position is pressured more by its own share loss than by category contraction, and the slide from a historical peak of #3 in January 2025 to #6 now implies a trajectory toward mid-pack status unless rank momentum reverses.
Notable Products
Blue Dream RSO Syringe (1g) posted the steepest decline in May 2026 at -30.3% MoM while sliding to rank 3, and Ice Cream Cake RSO Syringe (1g) also contracted by -11.9% MoM yet held rank 1; together these movements indicate pressure on Concentrates despite leadership at the top of the chart. Blue Dream RSO Tablets 40-Pack (1000mg) grew 4.9% MoM at rank 2, while Strawberry Cough RSO Tablets 20-Pack (1000mg) rose 12.1% MoM at rank 7, pointing to steadier demand in Capsules even as Blue Dream RSO Tincture (1000mg THC, 20ml) fell -15.1% MoM at rank 6. Four of the top ten are Capsules, and three are Tincture & Sublingual SKUs, which, combined with a $50,804 leader in Concentrates, implies a portfolio tilting toward dose-controlled formats while legacy syringes face volatility.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
